Premium
Intracellular Activation of Anticancer Therapeutics Using Polymeric Bioorthogonal Nanocatalysts
Author(s) -
Zhang Xianzhi,
Landis Ryan F.,
Keshri Puspam,
CaoMilán Roberto,
Luther David C.,
Gopalakrishnan Sanjana,
Liu Yuanchang,
Huang Rui,
Li Gengtan,
Malassiné Morgane,
Uddin Imad,
Rondon Brayan,
Rotello Vincent M.
Publication year - 2021
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.202001627
Subject(s) - bioorthogonal chemistry , prodrug , nanomaterial based catalyst , chemistry , combinatorial chemistry , catalysis , mitoxantrone , nanotechnology , biochemistry , materials science , click chemistry , biology , chemotherapy , genetics
Bioorthogonal catalysis provides a promising strategy for imaging and therapeutic applications, providing controlled in situ activation of pro‐dyes and prodrugs. In this work, the use of a polymeric scaffold to encapsulate transition metal catalysts (TMCs), generating bioorthogonal “polyzymes,” is presented. These polyzymes enhance the stability of TMCs, protecting the catalytic centers from deactivation in biological media. The therapeutic potential of these polyzymes is demonstrated by the transformation of a nontoxic prodrug to an anticancer drug (mitoxantrone), leading to the cancer cell death in vitro.